This week the Drug, Chemical & Associated Technologies Association (DCAT) will host DCAT Week 2025 in New York City, an annual event bringing together companies from across the bio/pharmaceutical manufacturing value chain. We sat down with Richard Sherwin, Antheia’s SVP of Commercialization, to learn more about the importance of the event for the future of the global pharma industry, and for our mission to end essential medicine shortages.
What makes DCAT Week such an important event for the pharma industry and companies like Antheia?
DCAT Week attracts senior executives from across the global pharma industry, making it a phenomenally efficient way for companies like ours to connect with the right people. We’re a lean team, so having an annual opportunity to meet with multiple partners in person is extremely valuable for achieving our commercialization goals. Bringing senior decision makers together helps move critical partnership discussions forward faster and ultimately advances our mission of ending drug shortages.
How have events like DCAT helped advance Antheia’s goals?
Antheia is introducing a highly differentiated technology that brings tangible benefits to the pharmaceutical industry. As our customers continue to receive our products, they are seeing the direct impact that our biomanufacturing platform has on the surety and agility of their supply chains. Leveraging a biomanufacturing platform to produce critical KSMs and APIs at commercial scale is a true industry first with once-in-a-generation potential to transform pharma supply chains. Having a dedicated week to meet with our customers and discuss our long-term goals as their next-gen KSM/API supplier brings us one step closer to a world with widespread access to essential medicines.
What are you looking forward to at this year’s DCAT?
Last year’s DCAT Week was extremely productive for Antheia and in the time since the 2024 event, we have reached some tremendous milestones, including our first commercial delivery of thebaine. We’re excited to give the industry an update on the maturity of our products, our commercial plans for 2025 and beyond, and the potential for our technology to make pharma supply chains more efficient and resilient. We also use this week to listen closely to industry leaders and better understand how their needs are evolving. Antheia’s platform brings an unmatched level of innovation and disruption to the pharma industry and it’s essential that we stay in lock-step with our customers to support them through this period of transformation.
What topics or trends do you anticipate being a focal point of DCAT this year?
We know that geopolitical uncertainties will be top of mind for many attendees, and we’re especially interested in advancing the conversation around the need to onshore essential medicine supply chains in the U.S. Antheia has an integral role to play in building more resilient, agile, and efficient pharmaceutical supply chains in the U.S. and around the world. We look forward to advancing conversations with our customers around how biomanufacturing will unlock the next evolution of pharma.
Follow Antheia on LinkedIn and X/Twitter, and drop us a comment if we’ll see you at DCAT Week 2025.